We comprehensively explored the clinical significance of PPAR-targeted genes and constructed and validated a novel PPAR signature, which showed the excellent performance in predicting prognosis and chemotherapy sensitivity of BLCA patients. This evidence concerns the gene PPARA and bladder transitional cell carcinoma.